DOCSLIB.ORG

Milger Et Al. Pulmonary CCR2+CD4+ T Cells Are Immune Regulatory And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Milger Et Al. Pulmonary CCR2+CD4+ T Cells Are Immune Regulatory And Milger et al. Pulmonary CCR2+CD4+ T cells are immune regulatory and attenuate lung fibrosis development Supplemental Table S1 List of significantly regulated mRNAs between CCR2+ and CCR2- CD4+ Tcells on Affymetrix Mouse Gene ST 1.0 array. Genewise testing for differential expression by limma t-test and Benjamini-Hochberg multiple testing correction (FDR < 10%). Ratio, significant FDR<10% Probeset Gene symbol or ID Gene Title Entrez rawp BH (1680) 10590631 Ccr2 chemokine (C-C motif) receptor 2 12772 3.27E-09 1.33E-05 9.72 10547590 Klrg1 killer cell lectin-like receptor subfamily G, member 1 50928 1.17E-07 1.23E-04 6.57 10450154 H2-Aa histocompatibility 2, class II antigen A, alpha 14960 2.83E-07 1.71E-04 6.31 10590628 Ccr3 chemokine (C-C motif) receptor 3 12771 1.46E-07 1.30E-04 5.93 10519983 Fgl2 fibrinogen-like protein 2 14190 9.18E-08 1.09E-04 5.49 10349603 Il10 interleukin 10 16153 7.67E-06 1.29E-03 5.28 10590635 Ccr5 chemokine (C-C motif) receptor 5 /// chemokine (C-C motif) receptor 2 12774 5.64E-08 7.64E-05 5.02 10598013 Ccr5 chemokine (C-C motif) receptor 5 /// chemokine (C-C motif) receptor 2 12774 5.64E-08 7.64E-05 5.02 10475517 AA467197 expressed sequence AA467197 /// microRNA 147 433470 7.32E-04 2.68E-02 4.96 10503098 Lyn Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 17096 3.98E-08 6.65E-05 4.89 10345791 Il1rl1 interleukin 1 receptor-like 1 17082 6.25E-08 8.08E-05 4.78 10580077 Rln3 relaxin 3 212108 7.77E-04 2.81E-02 4.77 10523156 Cxcl2 chemokine (C-X-C motif) ligand 2 20310 6.00E-04 2.35E-02 4.55 10456005 Cd74 CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)16149 8.54E-07 3.37E-04 4.40 10444291 H2-Ab1 histocompatibility 2, class II antigen A, beta 1 14961 5.90E-06 1.11E-03 4.35 10463070 Entpd1 ectonucleoside triphosphate diphosphohydrolase 1 12495 1.24E-07 1.26E-04 4.32 10469278 Il2ra interleukin 2 receptor, alpha chain 16184 1.63E-08 3.22E-05 4.30 10415392 Ltb4r1 leukotriene B4 receptor 1 16995 2.11E-06 5.94E-04 4.22 10409866 Ctla2b cytotoxic T lymphocyte-associated protein 2 beta 13025 4.72E-06 9.80E-04 4.10 10526832 LOC100504914 transmembrane protein PVRIG-like 100504914 7.25E-07 2.99E-04 4.03 10355403 Fn1 fibronectin 1 14268 4.92E-04 2.06E-02 4.02 10389214 Ccl9 chemokine (C-C motif) ligand 9 20308 4.33E-06 9.33E-04 3.97 10444298 H2-Eb1 histocompatibility 2, class II antigen E beta 14969 4.98E-07 2.32E-04 3.70 10454015 Ttc39c tetratricopeptide repeat domain 39C 72747 2.62E-06 6.72E-04 3.59 10598292 Foxp3 forkhead box P3 /// RIKEN cDNA 4930524L23 gene /// coiled-coil domain containing 2220371 4.38E-10 8.26E-06 3.59 10356299 Gpr55 G protein-coupled receptor 55 227326 2.26E-05 2.60E-03 3.53 10394674 Socs2 suppressor of cytokine signaling 2 /// suppressor of cytokine signaling 2 pseudogene216233 6.55E-07 2.74E-04 3.49 10360070 Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 14127 7.20E-04 2.66E-02 3.47 10368970 Prdm1 PR domain containing 1, with ZNF domain 12142 5.26E-08 7.64E-05 3.47 10409876 Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha 13024 2.32E-07 1.63E-04 3.44 10378286 Itgae integrin alpha E, epithelial-associated 16407 3.63E-06 8.07E-04 3.43 10523182 Areg amphiregulin 11839 1.02E-05 1.55E-03 3.42 10603328 Ccdc22 coiled-coil domain containing 22 /// forkhead box P3 54638 6.91E-10 8.26E-06 3.41 10598004 Ccr1 chemokine (C-C motif) receptor 1 12768 8.18E-06 1.36E-03 3.38 10484894 Ptprj protein tyrosine phosphatase, receptor type, J 19271 1.05E-06 3.84E-04 3.37 10527638 Alox5ap arachidonate 5-lipoxygenase activating protein 11690 5.16E-05 4.45E-03 3.37 10420308 Gzmb granzyme B 14939 1.38E-04 8.80E-03 3.37 10345241 Dst dystonin 13518 1.34E-09 8.54E-06 3.32 10487506 Gm14005 predicted gene 14005 100043424 4.30E-05 4.00E-03 3.31 10486875 Frmd5 FERM domain containing 5 228564 2.41E-06 6.53E-04 3.31 10358816 Lamc1 laminin, gamma 1 226519 1.05E-07 1.19E-04 3.30 10415081 FJ556972 1.21E-04 8.09E-03 3.23 10520121 FJ556972 1.21E-04 8.09E-03 3.23 10578405 FJ556972 1.21E-04 8.09E-03 3.23 10586076 FJ556972 1.21E-04 8.09E-03 3.23 10363070 Gp49a glycoprotein 49 A 14727 5.97E-07 2.55E-04 3.22 10518300 Tnfrsf1b tumor necrosis factor receptor superfamily, member 1b 21938 2.27E-07 1.63E-04 3.20 10421517 Cysltr2 cysteinyl leukotriene receptor 2 70086 6.52E-06 1.18E-03 3.18 10408935 Atxn1 ataxin 1 20238 3.56E-04 1.63E-02 3.18 10586781 Myo1e myosin IE 71602 4.86E-06 9.80E-04 3.15 10517508 C1qb complement component 1, q subcomponent, beta polypeptide 12260 5.35E-05 4.53E-03 3.13 10441436 Snx9 sorting nexin 9 66616 3.01E-07 1.71E-04 3.12 10355312 Ikzf2 IKAROS family zinc finger 2 22779 1.10E-06 3.85E-04 3.12 10569707 Myadm myeloid-associated differentiation marker 50918 3.41E-05 3.41E-03 3.11 10406270 Glrx glutaredoxin 93692 2.79E-07 1.71E-04 3.10 10587733 Ctsh cathepsin H 13036 2.05E-04 1.14E-02 3.10 10435704 Cd80 CD80 antigen 12519 2.60E-05 2.84E-03 3.10 10461558 Slc15a3 solute carrier family 15, member 3 65221 5.53E-07 2.46E-04 3.10 10466606 Anxa1 annexin A1 16952 2.63E-05 2.85E-03 3.08 10388591 Cpd carboxypeptidase D 12874 2.15E-06 5.94E-04 3.08 10569017 Ifitm3 interferon induced transmembrane protein 3 66141 3.87E-03 7.79E-02 3.08 10435907 Cd200r1 CD200 receptor 1 57781 1.89E-06 5.47E-04 3.07 10510580 Tnfrsf9 tumor necrosis factor receptor superfamily, member 9 21942 1.92E-05 2.32E-03 3.04 10405587 Tgfbi transforming growth factor, beta induced 21810 7.40E-05 5.86E-03 3.02 10539135 Capg capping protein (actin filament), gelsolin-like 12332 1.80E-05 2.22E-03 3.01 10580457 N4bp1 NEDD4 binding protein 1 80750 2.11E-05 2.51E-03 3.01 10588577 Cish cytokine inducible SH2-containing protein 12700 3.50E-07 1.88E-04 3.00 10521678 Cd38 CD38 antigen 12494 1.78E-04 1.04E-02 3.00 10509838 Padi2 peptidyl arginine deiminase, type II 18600 1.03E-05 1.56E-03 2.99 10346790 Ctla4 cytotoxic T-lymphocyte-associated protein 4 12477 1.70E-07 1.38E-04 2.98 10445977 Ebi3 Epstein-Barr virus induced gene 3 50498 1.55E-05 2.04E-03 2.95 10422728 Dab2 disabled homolog 2 (Drosophila) 13132 3.69E-04 1.67E-02 2.93 10586252 Dennd4a DENN/MADD domain containing 4A 102442 2.97E-07 1.71E-04 2.92 10597279 Ccrl2 chemokine (C-C motif) receptor-like 2 54199 5.43E-07 2.46E-04 2.90 10458581 Gm10008 predicted gene 10008 791268 9.40E-04 3.19E-02 2.90 10586240 Dennd4a DENN/MADD domain containing 4A 102442 2.09E-05 2.49E-03 2.88 10517513 C1qc complement component 1, q subcomponent, C chain 12262 2.08E-04 1.15E-02 2.88 10503334 Gem GTP binding protein (gene overexpressed in skeletal muscle) 14579 5.69E-04 2.27E-02 2.85 10355567 Tmbim1 transmembrane BAX inhibitor motif containing 1 69660 4.43E-05 4.07E-03 2.83 10401935 BC005685 cDNA sequence BC005685 352945 2.43E-04 1.26E-02 2.82 10381588 Grn granulin 14824 1.21E-05 1.70E-03 2.80 10590242 Ccr8 chemokine (C-C motif) receptor 8 12776 8.14E-05 6.26E-03 2.80 10542993 Pon3 paraoxonase 3 269823 1.35E-04 8.70E-03 2.79 10518313 Tnfrsf8 tumor necrosis factor receptor superfamily, member 8 21941 1.78E-03 4.83E-02 2.79 10371220 Gna15 guanine nucleotide binding protein, alpha 15 14676 2.11E-07 1.62E-04 2.78 10554863 Sytl2 synaptotagmin-like 2 83671 1.28E-05 1.76E-03 2.78 10547100 Plxnd1 plexin D1 67784 2.46E-07 1.67E-04 2.77 10379727 Gm11428 predicted gene 11428 100034251 6.09E-04 2.37E-02 2.75 10484888 Ptprj protein tyrosine phosphatase, receptor type, J 19271 3.49E-07 1.88E-04 2.75 10408937 Atxn1 ataxin 1 20238 3.34E-05 3.37E-03 2.75 10538901 BC005685 cDNA sequence BC005685 352945 3.39E-04 1.59E-02 2.74 10488589 Fam110a family with sequence similarity 110, member A 73847 2.42E-05 2.73E-03 2.74 10504757 BC005685 cDNA sequence BC005685 352945 1.26E-04 8.26E-03 2.74 10473281 Itgav integrin alpha V 16410 4.74E-06 9.80E-04 2.74 10387257 Alox8 arachidonate 8-lipoxygenase 11688 1.01E-06 3.72E-04 2.74 10389581 Ypel2 yippee-like 2 (Drosophila) 77864 4.12E-05 3.88E-03 2.74 10363082 Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 14728 8.98E-06 1.41E-03 2.71 10392142 Cd79b CD79B antigen 15985 1.38E-04 8.77E-03 2.71 10357833 Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 381290 7.62E-07 3.10E-04 2.70 10544660 Osbpl3 oxysterol binding protein-like 3 71720 4.73E-06 9.80E-04 2.69 10603551 Cybb cytochrome b-245, beta polypeptide 13058 1.16E-05 1.65E-03 2.69 10413928 1810011H11Rik RIKEN cDNA 1810011H11 gene 69069 4.58E-04 1.96E-02 2.66 10560624 Apoe apolipoprotein E 11816 1.97E-04 1.11E-02 2.64 10401968 Galc galactosylceramidase 14420 3.90E-05 3.73E-03 2.64 10572897 Hmox1 heme oxygenase (decycling) 1 15368 2.84E-06 6.78E-04 2.64 10367436 Cd63 CD63 antigen 12512 2.84E-03 6.44E-02 2.64 10383756 Ifitm2 interferon induced transmembrane protein 2 80876 7.30E-04 2.68E-02 2.62 10493820 S100a6 S100 calcium binding protein A6 (calcyclin) 20200 1.90E-05 2.31E-03 2.62 10592515 Ubash3b ubiquitin associated and SH3 domain containing, B 72828 8.71E-10 8.26E-06 2.61 10569014 Ifitm2 interferon induced transmembrane protein 2 80876 2.38E-04 1.25E-02 2.61 10593050 Il10ra interleukin 10 receptor, alpha 16154 1.30E-06 4.09E-04 2.60 10482687 Arl5a ADP-ribosylation factor-like 5A 75423 7.60E-06 1.29E-03 2.60 10350733 Rgs16 regulator of G-protein signaling 16 19734 1.43E-07 1.30E-04 2.60 10409278 Nfil3 nuclear factor, interleukin 3, regulated 18030 2.14E-04 1.16E-02 2.58 10474064 Trp53i11 transformation related protein 53 inducible protein 11 277414 1.44E-07 1.30E-04 2.57 10414262 Ear2 eosinophil-associated, ribonuclease A family, member 2 /// cDNA sequence BC15109313587 1.77E-04 1.04E-02 2.56 10418341 Il17rb interleukin 17 receptor B 50905 3.85E-05 3.70E-03 2.56 10403229
Load more

Recommended publications
  • Analysis of Gene Expression Data for Gene Ontology
    ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION A Thesis Presented to The Graduate Faculty of The University of Akron In Partial Fulfillment of the Requirements for the Degree Master of Science Robert Daniel Macholan May 2011 ANALYSIS OF GENE EXPRESSION DATA FOR GENE ONTOLOGY BASED PROTEIN FUNCTION PREDICTION Robert Daniel Macholan Thesis Approved: Accepted: _______________________________ _______________________________ Advisor Department Chair Dr. Zhong-Hui Duan Dr. Chien-Chung Chan _______________________________ _______________________________ Committee Member Dean of the College Dr. Chien-Chung Chan Dr. Chand K. Midha _______________________________ _______________________________ Committee Member Dean of the Graduate School Dr. Yingcai Xiao Dr. George R. Newkome _______________________________ Date ii ABSTRACT A tremendous increase in genomic data has encouraged biologists to turn to bioinformatics in order to assist in its interpretation and processing. One of the present challenges that need to be overcome in order to understand this data more completely is the development of a reliable method to accurately predict the function of a protein from its genomic information. This study focuses on developing an effective algorithm for protein function prediction. The algorithm is based on proteins that have similar expression patterns. The similarity of the expression data is determined using a novel measure, the slope matrix. The slope matrix introduces a normalized method for the comparison of expression levels throughout a proteome. The algorithm is tested using real microarray gene expression data. Their functions are characterized using gene ontology annotations. The results of the case study indicate the protein function prediction algorithm developed is comparable to the prediction algorithms that are based on the annotations of homologous proteins.
    [Show full text]
  • Differential Physiological Role of BIN1 Isoforms in Skeletal Muscle Development, Function and Regeneration
    bioRxiv preprint doi: https://doi.org/10.1101/477950; this version posted December 11, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Differential physiological role of BIN1 isoforms in skeletal muscle development, function and regeneration Ivana Prokic1,2,3,4, Belinda Cowling1,2,3,4, Candice Kutchukian5, Christine Kretz1,2,3,4, Hichem Tasfaout1,2,3,4, Josiane Hergueux1,2,3,4, Olivia Wendling1,2,3,4, Arnaud Ferry10, Anne Toussaint1,2,3,4, Christos Gavriilidis1,2,3,4, Vasugi Nattarayan1,2,3,4, Catherine Koch1,2,3,4, Jeanne Lainné6,7, Roy Combe2,3,4,8, Laurent Tiret9, Vincent Jacquemond5, Fanny Pilot-Storck9, Jocelyn Laporte1,2,3,4 1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France 2Centre National de la Recherche Scientifique (CNRS), UMR7104, Illkirch, France 3Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Illkirch, France 4Université de Strasbourg, Illkirch, France 5Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR-5310, INSERM U-1217, Institut NeuroMyoGène, 8 avenue Rockefeller, 69373 Lyon, France 6Sorbonne Université, INSERM, Institute of Myology, Centre of Research in Myology, UMRS 974, F- 75013, Paris, France 7Sorbonne Université, Department of Physiology, UPMC Univ Paris 06, Pitié-Salpêtrière Hospital, F- 75013, Paris, France 8CELPHEDIA-PHENOMIN, Institut Clinique de la Souris (ICS), Illkirch, France 9U955 – IMRB, Team 10 - Biology of the neuromuscular system, Inserm, UPEC, Ecole nationale vétérinaire d’Alfort, Maisons-Alfort, 94700, France 10Sorbonne Université, INSERM, Institute of Myology, Centre of Research in Myology, UMRS 794, F- 75013, Paris, France Correspondence to: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/477950; this version posted December 11, 2018.
    [Show full text]
  • Datasheet PB1029 Anti-AEBP2 Antibody
    Product datasheet Anti-AEBP2 Antibody Catalog Number: PB1029 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Basic Information Product Name Anti-AEBP2 Antibody Gene Name AEBP2 Source Rabbit IgG Species Reactivity human,mouse,rat Tested Application WB,IHC-P,ICC/IF,FCM Contents 500ug/ml antibody with PBS ，0.02% NaN3 , 1mg BSA and 50% glycerol. Immunogen E.coli-derived human AEBP2 recombinant protein (Position: K424-Q517). Human AEBP2 shares 98.8% amino acid (aa) sequence identity with mouse AEBP2. Purification Immunogen affinity purified. Observed MW 54KD Dilution Ratios Western blot: 1:500-2000 Immunohistochemistry(Paraffin-embedded Section): 1:50-400 Immunocytochemistry/Immunofluorescence (ICC/IF): 1:50-400 Flow cytometry (FCM): 1-3μg/1x106 cells Storage 12 months from date of receipt，-20℃ as supplied.6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing Background Information Adipocyte Enhancer-Binding Protein is a zinc finger protein that in humans is encoded by the evolutionarily well-conserved gene AEBP2. This gene is mapped to 12p12.3. AEBP2 is a DNA-binding transcriptional repressor. It may regulate the migration and development of the neural crest cells through the PRC2-mediated epigenetic mechanism and is most likely a targeting protein for the mammalian PRC2 complex. Reference Anti-AEBP2 Antibody被引用在0文献中。 暂无引用 FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC AND CLINICAL USE. 1 Product datasheet Anti-AEBP2 Antibody Catalog Number: PB1029 BOSTER BIOLOGICAL TECHNOLOGY Special NO.1, International Enterprise Center, 2nd Guanshan Road, Wuhan, China Web: www.boster.com.cn Phone: +86 27 67845390 Fax: +86 27 67845390 Email: [email protected] Selected Validation Data Figure 1.
    [Show full text]
  • Beta-Arrestin-Mediated Signaling in the Heart
    SPECIAL ARTICLE Circ J 2008; 72: 1725–1729 Beta-Arrestin-Mediated Signaling in the Heart Priyesh A. Patel, BS; Douglas G. Tilley, PhD*; Howard A. Rockman, MD*,** Beta-arrestin is a multifunctional adapter protein well known for its role in G-protein-coupled receptor (GPCR) desensitization. Exciting new evidence indicates thatβ-arrestin is also a signaling molecule capable of initiating its own G-protein-independent signaling at GPCRs. One of the best-studiedβ-arrestin signaling pathways is the one involvingβ-arrestin-dependent activation of a mitogen-activated protein kinase cascade, the extracellular regulated kinase (ERK). ERK signaling, which is classically activated by agonist stimulation of the epidermal growth factor receptor (EGFR), can be activated by a number of GPCRs in aβ-arrestin-dependent manner. Recent work in animal models of heart failure suggests thatβ-arrestin-dependent activation of EGFR/ERK signaling by theβ-1-adrenergic receptor, and possibly the angiotensin II Type 1A receptor, are cardioprotective. Hence, a new model of signaling at cardiac GPCRs has emerged and implicates classical G-protein-mediated signaling with promoting harmful remodeling in heart failure, while concurrently linkingβ-arrestin-dependent, G-protein-inde- pendent signaling with cardioprotective effects. Based on this paradigm, a new class of drugs could be identified, termed “biased ligands”, which simultaneously block harmful G-protein signaling, while also promoting cardio- protectiveβ-arrestin-dependent signaling, leading to a potential breakthrough
    [Show full text]
  • BMC Evolutionary Biology Biomed Central
    BMC Evolutionary Biology BioMed Central Research article Open Access On the origins of arrestin and rhodopsin Carlos E Alvarez1,2,3 Address: 1Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, 43205, USA, 2Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, 43210, USA and 3Novartis Institutes of BioMedical Research, CH-4002 Basel, Switzerland Email: Carlos E Alvarez - [email protected] Published: 29 July 2008 Received: 11 January 2008 Accepted: 29 July 2008 BMC Evolutionary Biology 2008, 8:222 doi:10.1186/1471-2148-8-222 This article is available from: http://www.biomedcentral.com/1471-2148/8/222 © 2008 Alvarez; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: G protein coupled receptors (GPCRs) are the most numerous proteins in mammalian genomes, and the most common targets of clinical drugs. However, their evolution remains enigmatic. GPCRs are intimately associated with trimeric G proteins, G protein receptor kinases, and arrestins. We conducted phylogenetic studies to reconstruct the history of arrestins. Those findings, in turn, led us to investigate the origin of the photosensory GPCR rhodopsin. Results: We found that the arrestin clan is comprised of the Spo0M protein family in archaea and bacteria, and the arrestin and Vps26 families in eukaryotes. The previously known animal arrestins are members of the visual/beta subfamily, which branched from the founding "alpha" arrestins relatively recently.
    [Show full text]
  • The Role and Mechanisms of Action of Micrornas in Cancer Drug Resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6*
    Si et al. Clinical Epigenetics (2019) 11:25 https://doi.org/10.1186/s13148-018-0587-8 REVIEW Open Access The role and mechanisms of action of microRNAs in cancer drug resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6* Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can regulate various target genes and are thus involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. Drug resistance in cancer chemotherapy is one of the main obstacles to curing this malignant disease. Statistical data indicate that over 90% of the mortality of patients with cancer is related to drug resistance. Drug resistance of cancer chemotherapy can be caused by many mechanisms, such as decreased antitumor drug uptake, modified drug targets, altered cell cycle checkpoints, or increased DNA damage repair, among others. In recent years, many studies have shown that miRNAs are involved in the drug resistance of tumor cells by targeting drug-resistance-related genes or influencing genes related to cell proliferation, cell cycle, and apoptosis. A single miRNA often targets a number of genes, and its regulatory effect is tissue-specific. In this review, we emphasize the miRNAs that are involved in the regulation of drug resistance among different cancers and probe the mechanisms of the deregulated expression of miRNAs. The molecular targets of miRNAs and their underlying signaling pathways are also explored comprehensively. A holistic understanding of the functions of miRNAs in drug resistance will help us develop better strategies to regulate them efficiently and will finally pave the way toward better translation of miRNAs into clinics, developing them into a promising approach in cancer therapy.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • ) (51) International Patent Classification: Columbia V5G 1G3
    ) ( (51) International Patent Classification: Columbia V5G 1G3 (CA). PANDEY, Nihar R.; 10209 A 61K 31/4525 (2006.01) C07C 39/23 (2006.01) 128A St, Surrey, British Columbia V3T 3E7 (CA). A61K 31/05 (2006.01) C07D 405/06 (2006.01) (74) Agent: ZIESCHE, Sonia et al.; Gowling WLG (Canada) A61P25/22 (2006.01) LLP, 2300 - 550 Burrard Street, Vancouver, British Colum¬ (21) International Application Number: bia V6C 2B5 (CA). PCT/CA2020/050165 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection av ailable) . AE, AG, AL, AM, 07 February 2020 (07.02.2020) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 16/270,389 07 February 2019 (07.02.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (63) Related by continuation (CON) or continuation-in-part SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (CIP) to earlier application: TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. US 16/270,389 (CON) (84) Designated States (unless otherwise indicated, for every Filed on 07 Februaiy 2019 (07.02.2019) kind of regional protection available) .
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Murine Megakaryopoiesis Is Critical for P21 SCL-Mediated Regulation Of
    From bloodjournal.hematologylibrary.org at UNIVERSITY OF BIRMINGHAM on March 1, 2012. For personal use only. 2011 118: 723-735 Prepublished online May 19, 2011; doi:10.1182/blood-2011-01-328765 SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis Hedia Chagraoui, Mira Kassouf, Sreemoti Banerjee, Nicolas Goardon, Kevin Clark, Ann Atzberger, Andrew C. Pearce, Radek C. Skoda, David J. P. Ferguson, Steve P. Watson, Paresh Vyas and Catherine Porcher Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/118/3/723.full.html Articles on similar topics can be found in the following Blood collections Platelets and Thrombopoiesis (260 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved. From bloodjournal.hematologylibrary.org at UNIVERSITY OF BIRMINGHAM on March 1, 2012. For personal use only. PLATELETS AND THROMBOPOIESIS SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis Hedia Chagraoui,1 *Mira Kassouf,1 *Sreemoti Banerjee,1 Nicolas Goardon,1 Kevin Clark,1 Ann Atzberger,1 Andrew C.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]